Transamination is a Major Pathway of L-Dopa Metabolism following Peripheral Decarboxylase Inhibition
- 1 February 1974
- journal article
- Published by Springer Nature in Nature
- Vol. 247 (5440) , 364-366
- https://doi.org/10.1038/247364b0
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- DOPAMINE IN THE BASAL GANGLIA: Its Role and Therapeutic Implications (Including the Clinical Use of L-DOPA)British Medical Bulletin, 1973
- Peripheral Aromatic L-Amino Acids Decarboxylase Inhibitor in Parkinsonism. I. EFFECT ON O-METHYLATED METABOLITES OF L-DOPA-2-14CJournal of Clinical Investigation, 1972
- Gas chromatographic assay of phenolic alcohols in biological material using electron capture detectionBiochemical Medicine, 1971
- Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with LevodopaBMJ, 1971
- LevodopaDrugs, 1971
- The metabolism of orally administered l‐DOPA in ParkinsonismBritish Journal of Pharmacology, 1969
- Gas chromatographic measurement of phenolic acids and alcohols in human urineClinica Chimica Acta; International Journal of Clinical Chemistry, 1968
- Inhibition of dopa decarboxylase by the hydrazino analog of α-methyldopaBiochemical Pharmacology, 1962
- A new inhibitor of decarboxylase of aromatic amino acidsCellular and Molecular Life Sciences, 1962
- Blood-Brain Barrier for AdrenalineScience, 1959